Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980428 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
A Phase 1 study of Healthy Participants and Dyslipidemia, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
- 5
- Study locations
NCT06980428: Recruiting Phase 1 study of Healthy Participants and Dyslipidemia, sponsored by AstraZeneca.
NCT06980428 is a Phase 1 study of Healthy Participants and Dyslipidemia that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 136 participants, above the 64-participant average among 119 other Healthy Participants trials with a reported enrollment target (113% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06980428, a Phase 1 study of Healthy Participants and Dyslipidemia, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\[a\]) levels and participants with dyslipidemia.
Primary Outcome
To assess the safety and tolerability of AZD4954 following oral administration of SAD (Part A).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD4954
Study Locations (5)
Florida
- Research Site - Inverness
- Research Site - Jacksonville
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2026-12-04 |
| Phase | Phase 1 |
What NCT06980428 shows while recruiting
NCT06980428 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 119 other Healthy Participants trials with a reported enrollment target (113% higher).
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06980428 lists 5 locations in 4 states (Florida, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT06980428 about?
NCT06980428 is a clinical study titled "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia". The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4954 in healthy participants with or without elevated Lipoprotein(a) (Lp\[a\]) levels and participants with dyslipidemia.
What is the current status of trial NCT06980428?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2025-05-27. Estimated completion is 2026-12-04.
What conditions does trial NCT06980428 study?
This clinical trial studies the following conditions: Healthy Participants, Dyslipidemia.
What interventions are being tested in trial NCT06980428?
The interventions under investigation include: Placebo (DRUG), AZD4954 (DRUG).
Who is sponsoring clinical trial NCT06980428?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980428 being conducted?
This trial has 5 study locations across California, Florida, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06980428's enrollment target sits among peer trials
136 10th of 119 higher than 110 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI